PPM1D and non-small cell lung carcinoma: These studies revealed novel genetic alterations, along with the associated signaling pathway, that promote CSC properties in NSCLC development, and identified novel mechanisms underlying the oncogenic activity of WIP1 and the anticancer efficacy of WIP1 inhibitors, which may expand the therapeutic application of WIP1 inhibitors.